

Date: NOV . 1, 2002

From: LISA HAZZANG

Fax:

Zip:

Total Pages (including cover): If you do not receive all pages, please contact

EDWARDS & ANGELL, LLP

101 FEDERAL STREET BOSTON, MA 02110 TELEPHONE: (617) 439-4444 FAX: (617) 439-4170 OR (617) 439-7748

The second secon
rastava
DIRECT NUMBER:
DIRECT NUMBER:
DIRECT NUMBER:

USSN 09/669,051

Proposed claims for discussion during Nov. 5,2002 Interview (10:00am)

Confidentiality Note

This facsimile contains privileged and confidential information intended only for the use of the individual or entity ants justimize commins provinced and conjugation agreement and the employee or agent responsible named above. If the reader of this faceimile is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination or copying of this facsimile is spirity prohibited. If you have received this facsimile in error, please notify is immediately by telephone (call collect) and return the original farsimile to us at the above address via the U.S. Postal Service. We will reimburse you for postage. Thank you.

BOSTON FE LAUDERDALE HARTFORD LONDON NEW YORK PROVIDENCE SHORTHILLS, NJ WEST PALM BEACH

USSN: 09/669,051

PROPOSED CLAIMS FOR DISCUSSION (NOVEMBER 5, 2002 INTERVIEW)

- A method for treating an obstructed biological conduit, comprising administering to the wall of the biological conduit an agent that can degrade the extracellular matrix of obstructing tissue, wherein administration of the agent results in proteolysis of clastin and/or clastin microfibers in the wall of the biological conduit.
- The method of claim 1, wherein the biological conduit is an artery or vein that is
 obstructed or susceptible to obstruction.
- The method of claim 1, wherein administration of the agent comprises inserting a
 delivery apparatus into the wall of the biological conduit.
- 4. The method of claim 3, wherein the method further comprises the step of localizing the delivery apparatus in close proximity to the obstructed segment of the biological conduit to be treated.
- The method of claim 1, wherein the protoolysis of clastin and/or elastin microfibers in the wall of the biological conduit leads to enlargement of the diameter of the treated biological conduit.
- The method of claim 1 wherein the lumen of the biological conduit is pressurized while elastin and/or elastin microfibers in the wall are undergoing proteolysis.
- The method of claim 1 wherein the agent stimulates the release of endogenous enzymes that hydrolyzes clastin and/or elastin microfibers.